M
Marker Therapeutics, Inc.
MRKRCIK 0001094038NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-12.16M
Total Assets
$19.07M
Equity
$16.80M
Shares Out
16.67M
Op. Cash Flow
$-12.01M
Business
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing T cell‑based therapies that expand natural tumor‑specific T cells to treat hematologic malignancies and solid tumors. It offers non‑genetically engineered multi antigen recognizing (MAR‑T) cell products, including autologous MT‑601 (lymphoma and pancreatic cancer) and off‑the‑shelf MT‑401‑OTS (AML/MDS). Its operations are organized around clinical development, manufacturing and an OTS product program, with technology licensed from Baylor College of Medicine and third‑party manufacturing partnerships. Marker distributes investigational products to U.S. clinical trial sites and plans HLA‑matched banked inventory for rapid clinical delivery.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 4 | 7 | 3 | 4 | 1 | |
| Research and development | 12 | 13 | 10 | 12 | 28 | |
| General and administrative | 4 | 4 | 7 | 11 | 13 | |
| Loss on early termination of vendor agreement | 453,135 | — | — | — | — | |
| Total operating expenses | 16 | 18 | 18 | 23 | 41 | |
| Loss from operations | −13 | −11 | −15 | −20 | −39 | |
| Interest income | 594,206 | 437,010 | 539,158 | 248,063 | 5,700 | |
| Other income | 117,444 | — | — | — | — | |
| Loss from operations before income taxes | −12 | −11 | −14 | −20 | — | |
| Income tax (benefit) expense | −15,156 | 49,953 | 4,000 | — | — | |
| Net loss | −12 | −11 | −8 | −30 | −42 | |
| Net loss per share, basic (in dollars per share) | −0.79 | −1.19 | −0.94 | −3.58 | −5.47 | |
| Net loss per share, diluted (in dollars per share) | −0.79 | −1.19 | −0.94 | −3.58 | −5.47 | |
| Basic (in shares) | 15 | 9 | 9 | 8 | 8 | |
| Diluted (in shares) | 15 | 9 | 9 | 8 | 8 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 16 | 19 | 15 | 12 | 42 | |
| Restricted cash | 1 | 0 | — | 0 | 1 | |
| Prepaid expenses and deposits | 658,750 | 483,717 | — | — | — | |
| Other receivables | 1 | 2 | 1 | 2 | 237 | |
| Total current assets | 19 | 22 | 17 | 17 | 46 | |
| Total assets | 19 | 22 | 17 | 34 | 68 | |
| Accounts payable and accrued liabilities | 1 | 2 | 2 | 3 | 11 | |
| Related party payable | — | 2 | 1 | — | — | |
| Deferred revenue | 974,799 | — | — | 0 | 1 | |
| Total current liabilities | 2 | 3 | 3 | 8 | 13 | |
| Total liabilities | 2 | 3 | 3 | 15 | 24 | |
| Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — | — | — | — | |
| Common stock, $0.001 par value, 30 million shares authorized, 16.7 million and 10.7 million shares issued and outstanding as of December 31, 2025 and 2024, respectively (see Note 7) | 16,672 | 10,708 | 8,891 | 8,406 | 8,308 | |
| Additional paid-in capital | 476 | 466 | 450 | 448 | 442 | |
| Accumulated deficit | −459 | −447 | −436 | −428 | −398 | |
| Total stockholders' equity | 17 | 19 | 14 | 20 | 44 | |
| Total liabilities and stockholders' equity | 19 | 22 | 17 | 34 | 68 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −12 | −11 | −8 | −30 | −42 | |
| Stock-based compensation | 537,540 | 245,864 | 858,269 | 3 | 6 | |
| Prepaid expenses and deposits | −175,033 | 504,409 | — | — | — | |
| Other receivables | 977,303 | −1 | — | — | — | |
| Related party payable | −2 | 380,845 | 1 | 3 | — | |
| Accounts payable and accrued expenses | −454,570 | 8,761 | −718,393 | −1 | 4 | |
| Deferred revenue | 974,799 | — | — | −1 | 1 | |
| Net cash used in operating activities | −12 | −11 | −16 | −27 | −27 | |
| Proceeds from issuance of common stock, net | 10 | 15 | 1 | 202,130 | 53 | |
| Proceeds from exercise of warrants and stock options | 605 | 62,159 | — | — | — | |
| Net cash provided by financing activities | 10 | 15 | 1 | 202,130 | 53 | |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | −2 | 4 | 3 | −32 | 22 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro